Cancer biologists bring in the B-cell reinforcements for immunotherapy

Cancer biologists are exploring new avenues for immunotherapy by focusing on B cells, a type of immune cell that has long been overlooked. Immunotherapy harnesses the body's immune system to fight cancer, often by boosting the performance of adaptive immune cells called T cells. However, not all patients respond to standard T cell immunotherapies, prompting researchers to seek alternative approaches.

One such approach is to utilize B cells, which have the ability to regulate killer T cell function. A recent study published in Cell Reports by scientists at the Salk Institute reveals that B cells can help bring cancer-killing T cells into tumors, organize them, and enhance their cytotoxic function. This discovery could potentially revolutionize cancer care by providing a new pathway to enhance the immune system's attack on cancer cells.

The research, led by Daniel Hollern, a scientist at the Salk Institute, involved investigating the interactions between B cells and CD40, a protein that interacts with CD40 ligand on the surface of immune cells. The study found that B cells can help recruit CD8+ T cells to tumors and direct their organization within tumors. Additionally, B cells can directly signal to CD8+ T cells to turn on their killer functions, thereby enhancing their ability to eliminate cancer cells.

These findings highlight the importance of B cells in cancer immunotherapy and suggest that B cells may be a potent clinical target for cancer therapeutics. The research opens up new possibilities for improving the effectiveness of immunotherapy in patients who do not respond to standard T cell immunotherapies. As Hollern notes, "We've exposed that B cells can regulate CD8+ T cells to drive tumor cell killing, but we need to figure out how to optimize B cell function to unleash their full capacity to eliminate cancer."